"10.1371_journal.pone.0077780","plos one","2013-10-21T00:00:00Z","Edward Seung; Timothy E Dudek; Todd M Allen; Gordon J Freeman; Andrew D Luster; Andrew M Tager","Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, United States of America; Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, United States of America; Pulmonary and Critical Care Unit, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, United States of America; Ragon Institute of MGH, Massachusetts Institutes of Technology, and Harvard, Cambridge, Massachusetts, United States of America; Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America","Conceived and designed the experiments: ES AMT. Performed the experiments: ES TED. Analyzed the data: ES TED ADL AMT. Contributed reagents/materials/analysis tools: TMA GJF. Wrote the paper: ES AMT.","GJF receives royalties from patents regarding the PD-1 pathway. All other authors have declared that no competing interests exist. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. The authors have also included the patent names and numbers for which GJF receives royalties as requested in the following table: List of licensed PD-1 pathway patents. Note that B7-4 is now called PD-L1. 1) Nucleic acids encoding costimulatory molecule B7-4: United States patent US 6936704. 2) B7-4 polypeptides and uses, therefore, United States patent US 7038013. 3) PD-1, a receptor for B7-4, and uses, therefore, United States patent US 7101550. 4) Methods for screening for compounds that modulate PD-1 signaling: United States patent US 7105328. 5) Methods of identifying compounds that upmodulate Tcell activation in the presence of a PD-1 mediated signal: United States patent US 7432059. 6) B7-4 Antibodies and uses therefore United States patent US 7635757. 7) Methods of upmodulating an immune response with non-activating forms of B7-4: United States patent US 7638492. 8) Methods for screening for compounds that modulate PD-1 signaling: United States patent US 7700301. 9) Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1: United States patent US 7709214. 10) Agents that modulate the interaction of B7-1 polypeptide with PD-L1 and methods of use thereof: United States patent US 7722868.","2013","10","Edward Seung","ES",6,FALSE,2,2,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
